Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 224

The DOI matches its Crossref record.

A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer

Open access
Alumkal, Joshi J., Slottke, Rachel, Schwartzman, Jacob, Cherala, Ganesh, Munar, Myrna, Graff, Julie N., Beer, Tomasz M., Ryan, Christopher W., Koop, Dennis R., Gibbs, Angela, Gao, Lina, Flamiatos, Jason F., Tucker, Erin, Kleinschmidt, Richard, Mori, Motomi · 2015 · Investigational New Drugs

Abstract

IntroductionDiets high in cruciferous vegetables are associated with lower risk of incidence of prostate cancer, including aggressive forms of this disease. Human intervention studies with cruciferous vegetable-rich diets also demonstrate modulation of gene expression in important pathways in prostate cells.PurposeSulforaphane is a constituent of these foods postulated to harbor the anti-neoplastic activity based on multiple tumor models. Our own work demonstrates that sulforaphane inhibits AR signaling in prostate cancer cells. Here, we report results from the first clinical trial of sulforaphane-rich extracts in men with prostate cancer.MethodsWe treated 20 patients who had recurrent prostate cancer with 200 μmoles/day of sulforaphane-rich extracts for a maximum period of 20 weeks and determined the proportion of patients with ≥50 % PSA declines, the primary endpoint. Only one subject experienced a ≥50 % PSA decline. Thus, the primary endpoint was not achieved. Seven patients experienced smaller PSA declines (<50 %). There was also a significant lengthening of the on-treatment PSA doubling time (PSADT) compared with the pre-treatment PSADT [6.1 months pre-treatment vs. 9.6 months on-treatment (p = 0.044)]. Finally, treatment with sulforaphane-rich extracts was safe with no Grade 3 adverse events.ConclusionsTreatment with 200 μmoles/day of sulforaphane-rich extracts did not lead to ≥50 % PSA declines in the majority of patients. However, because of the safety of treatment and the effects on PSADT modulation, further studies, including those with higher doses, may be warranted to clarify the role of sulforaphane as a prevention agent or treatment agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10637-014-0189-z

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 224

Metadata

Authors
Alumkal, J. J., Slottke, R., Schwartzman, J., Cherala, G., Munar, M., Graff, J. N., Beer, T. M., Ryan, C. W., Koop, D. R., Gibbs, A., Gao, L., Flamiatos, J. F., Tucker, E., Kleinschmidt, R., & Mori, M.
Venue
Investigational New Drugs
Published
2014-11-29
Volume
33
Issue
2
Pages
480-489
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2090764585
Cited by
224
References
0
FWCI
8.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. https://app.cochat.ai/papers/10.1007/s10637-014-0189-z
The paper
Alumkal, J. J., Slottke, R., Schwartzman, J., Cherala, G., Munar, M., Graff, J. N., Beer, T. M., Ryan, C. W., Koop, D. R., Gibbs, A., Gao, L., Flamiatos, J. F., Tucker, E., Kleinschmidt, R., & Mori, M. (2015). A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-014-0189-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.